ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2017
Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 111 citations in OpenAlex.
- Systematic surveillance of Carbapenemase-producing Enterobacterales reveals persistent spread of IMP-4 IncM2 plasmids in New Caledonia.Communications medicine · 2026Article
- Beyond the Spotlight:Antibiotics (Basel, Switzerland) · 2025Review
- Emergence and Polyclonal Dissemination of blaEmerging infectious diseases · 2025Article
- The magnitude of MDR carbapenemase-producing Enterobacteriaceae isolates and associated factors among hospitalized patients of Northeast Ethiopia.JAC-antimicrobial resistance · 2025Article
- Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France.The Journal of antimicrobial chemotherapy · 2025Article
- Article
- Epidemiological and genomic characteristics of global blaNDM-carrying Escherichia coli.Annals of clinical microbiology and antimicrobials · 2024Article
- [DISTRIBUTION OF CARBAPENEMASES IN TUNISIAN BURN PATIENTS].Annals of burns and fire disasters · 2024Article
- Antibiotic definitive treatment in ventilator associated pneumonia caused by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter observational study.Critical care (London, England) · 2024Observational
- Epidemiology and Resistance Phenotypes of Carbapenem-ResistantMicroorganisms · 2023Article
- High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistantIranian journal of microbiology · 2023Article
- Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.BMC microbiology · 2023Article
- Evaluation of a colorimetric test for the rapid detection of carbapenemase activity in Gram negative bacilli: the MAST® PAcE test.Antimicrobial agents and chemotherapy · 2023Article
- Molecular surveillance reveals the emergence and dissemination of NDM-5-producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Limiting the Spread of Multidrug-Resistant Bacteria in Low-to-Middle-Income Countries: One Size Does Not Fit All.Pathogens (Basel, Switzerland) · 2023Review
- Synergistic Effects of Capric Acid and Colistin against Colistin-Susceptible and Colistin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Activity of mecillinam against carbapenem-resistant Enterobacterales.The Journal of antimicrobial chemotherapy · 2022Article
- Does Protocatechuic Acid Affect the Activity of Commonly Used Antibiotics and Antifungals?Life (Basel, Switzerland) · 2022Article
- Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017-2019.Antimicrobial resistance and infection control · 2022Article
- Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-ResistantFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2014, a total of 2,976 Enterobacteriaceae isolates with decreased susceptibility to carbapenems were received at the French Associated National Reference Center for Antibiotic Resistance (NRC) and were characterised for their molecular resistance mechanism to carbapenems and compared with results obtained during 2012 and 2013.The overall number of enterobacterial isolates with decreased susceptibility to carbapenems received at the NRC rapidly increased (more than twofold in two years) with a growing proportion of carbapenemase producers (23.1% in 2012 vs 28.6% in 2013 vs 36.2% in 2014). Between 2012 and 2014, the main carbapenemase type was OXA-48, with an increase in OXA-48 variants (mostly OXA-181) and NDM producers, whereas the number KPC producers decreased. We identified a potential spread of OXA-181 producers in the tropical region of Africa. Finally, OXA-48 and OXA-48-related enzymes remained the predominant carbapenemases in France. The number of carbapenemase-producing Escherischia coli isolates was multiplied by fivefold between 2012 and 2014, suggesting a possible dissemination in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.